J Neuroimmunol. 2003 Jul;140(1-2):216-21
Gomez-Lira M, Liguori M, Magnani C, Bonamini D, Salviati A, Leone M, Andreoli V, Trojano M, Valentino P, Savettieri G, Quattrone A, Pignatti PF, Momigliano-Richiardi P, Giordano M.
Dipartimento Materno Infantile e di Biologia-Genetica, Sezione di Biologia e Genetica, Universita di Verona, Verona, Italy
We re-evaluated the association with multiple sclerosis (MS) of the C77G splicing regulatory variation in the CD45 gene and screened for new mutations the three alternatively spliced exons (#4, 5 and 6).
No association with C77G was detected in two groups of patients (total=448) and controls (total=559) from Northern and Southern Italy.
When excluding the first published study indicating a positive association, a meta-analysis of the five further studies conducted to date (including the present one) led to a non-significant combined odds ratio (OR) of 1.11.
None of the four newly identified nucleotide substitutions, namely C77T (Pro59Pro) in exon 4, G69C (Asp121His) in exon 5, T127A (Ile187Asn) and A138G (Thr191Ala) in exon 6, was significantly associated to MS.